Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S63-9. doi: 10.1016/j.amepre.2012.09.045.


During the past few years, much has been learned about pre-exposure prophylaxis (PrEP) of HIV from studies conducted in the U.S. and elsewhere. A review and summary was conducted of articles and reports published through August 2012 on the safety and efficacy of PrEP in humans; U.S.-based studies assessing PrEP knowledge, attitudes, and use among at-risk populations and healthcare providers; and models of the cost effectiveness of PrEP. PrEP is generally safe and effective and may be cost effective in a targeted population. Awareness and interest in PrEP are increasing. PrEP is an important new addition to HIV prevention services, but continued study is warranted.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Administration, Oral
  • Anti-HIV Agents / administration & dosage*
  • Clinical Trials as Topic*
  • HIV Infections / prevention & control*
  • HIV Infections / transmission
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Primary Prevention


  • Anti-HIV Agents